- Aurobindo Pharma‘s net income for the 2nd quarter was 8.48 billion rupees, which represents a 3.8% increase year over year.
- This net income figure fell short of analysts’ estimates, which were set at 8.97 billion rupees.
- The company’s revenue for the quarter was 82.9 billion rupees, exceeding the estimated 81.5 billion rupees and marking a 6.3% increase year over year.
- Total costs for Aurobindo Pharma during the quarter rose by 6% year over year, reaching 71.3 billion rupees.
- Other income saw a decline of 11% year over year, amounting to 1.21 billion rupees.
- Market sentiment on Aurobindo Pharma showed 22 buy recommendations, 1 hold, and 5 sell recommendations.
A look at Aurobindo Pharma Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts indicate a promising long-term outlook for Aurobindo Pharma as it garners impressive scores across various factors. With a strong Value score of 4, the company is deemed to offer favorable investment opportunities relative to its price. Aurobindo Pharma also demonstrates robust Resilience and Momentum with scores of 4, reflecting its ability to withstand market uncertainties and maintain a positive growth trajectory. While Growth and Dividend scores stand at 3, indicating moderate performance in these areas, the overall outlook appears optimistic for the pharmaceutical manufacturer.
Aurobindo Pharma Limited, known for manufacturing oral and sterile antibiotics, anti-ulcerants, and generic basic drugs, receives notable commendation across key investment factors. The company’s diverse product portfolio includes essential medications such as semi-synthetic penicillins and formulations like astemizole and omeprazole. With solid scores in Value, Resilience, and Momentum, Aurobindo Pharma is positioned as a strong contender in the pharmaceutical sector, poised for long-term success based on the Smartkarma Smart Scores evaluation.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
